ASH 2019 | Promising combination for kappa-restricted RRMM: kappamab, len, dex
Andrew Spencer
• 7 Dec 2019
Kappamab is a chimeric IgG1 monoclonal antibody specific for kappa myeloma antigen (KMA), a tumor-specific antigen exclusively expressed on the surface of kappa-restricted multiple myeloma (MM) cells. Andrew Spencer, MBBS, FRACP FRCPA, DM, Alfred Health-Monash University, Melbourne, Australia, discusses the rationale and results of a phase IIb, open-label, sequential cohort study comparing kappamab alone to kappamab in combination with lenalidomide and low dose dexamethasone in relapsed/refractory MM. Results indicate that this novel combination may represent a promising new therapeutic option. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
